FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies.
Cedars-Sinai Neurology
Latest Content
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
4
First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy
5